Advertisement
BMRA vs STIM
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMRA is a Hold and STIM is a Hold.
BMRA sees MACD Histogram crosses below signal line
BMRA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 25, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 41 instances where the indicator turned negative. In 40 of the 41 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BMRA as a result. In 76 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
BMRA moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BMRA crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
BMRA broke above its upper Bollinger Band on September 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +10.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMRA advanced for three days, in 175 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 87 of 115 cases where BMRA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.179) is normal, around the industry mean (10.930). P/E Ratio (0.000) is within average values for comparable stocks, (100.178). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.578) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. BMRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Momentum Indicator for STIM turns negative, indicating new downward trend
STIM saw its Momentum Indicator move below the 0 level on September 21, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In 72 of the 80 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
STIM moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for STIM crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STIM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for STIM entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where STIM advanced for three days, in 228 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
STIM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.905) is normal, around the industry mean (10.930). P/E Ratio (0.000) is within average values for comparable stocks, (100.178). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.250) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. STIM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STIM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
BMRA | STIM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 68 | 54 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 32 Undervalued | 42 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 99 | |
PRICE GROWTH RATING 1..100 | 63 | 63 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMRA's Valuation (32) in the Medical Specialties industry is in the same range as STIM (42). This means that BMRA’s stock grew similarly to STIM’s over the last 12 months.
BMRA's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as STIM (100). This means that BMRA’s stock grew similarly to STIM’s over the last 12 months.
BMRA's SMR Rating (98) in the Medical Specialties industry is in the same range as STIM (99). This means that BMRA’s stock grew similarly to STIM’s over the last 12 months.
BMRA's Price Growth Rating (63) in the Medical Specialties industry is in the same range as STIM (63). This means that BMRA’s stock grew similarly to STIM’s over the last 12 months.
BMRA's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as STIM (100). This means that BMRA’s stock grew similarly to STIM’s over the last 12 months.
| BMRA | STIM | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 75% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 77% | 1 day ago 89% |
| Momentum ODDS (%) | 1 day ago 88% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 90% | N/A |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 87% |
| TrendMonth ODDS (%) | 1 day ago 88% | 1 day ago 88% |
| Advances ODDS (%) | 25 days ago 76% | 11 days ago 88% |
| Declines ODDS (%) | 1 day ago 87% | 3 days ago 89% |
| BollingerBands ODDS (%) | 1 day ago 89% | 1 day ago 81% |
| Aroon ODDS (%) | 1 day ago 76% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMRA’s FA Score shows that 1 FA rating(s) are green while STIM’s FA Score has 0 green FA rating(s).
- BMRA’s FA Score: 1 green, 4 red.
- STIM’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMRA’s TA Score shows that 4 TA indicator(s) are bullish while STIM’s TA Score has 4 bullish TA indicator(s).
- BMRA’s TA Score: 4 bullish, 6 bearish.
- STIM’s TA Score: 4 bullish, 5 bearish.
Price Growth
BMRA (@Medical/Nursing Services) experienced а -2.70% price change this week, while STIM (@Medical/Nursing Services) price change was -8.88% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.72%. For the same industry, the average monthly price growth was -5.75%, and the average quarterly price growth was -13.54%.
Reported Earning Dates
STIM is expected to report earnings on Nov 10, 2026.
Industries' Descriptions
@Medical/Nursing Services (-2.72% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement